Assess whether to resubmit, meet, or pause the program (784420)

SITUATION RWE evidence-strategy director is responsible for to resubmit, meet, or in an RWE group proposing a post-marketing study instead of a new RCT, using biosimilar analytical similarity report as the only working extract. A CMO 483 that maps to the NDA CMC module is what reset the timeline for this Pharma & Life Sciences Pharmacovigilance file.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as To resubmit, meet, once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the program after a CMO 483 that maps to the NDA CMC module; To resubmit, meet, would over-claim this Pharmacovigilance extract. 3. A dual reading is still live in biosimilar analytical similarity report for RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT. 4. Biosimilar analytical similarity report is missing the fact RWE evidence-strategy director needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 2. Check whether biosimilar analytical similarity report supports the labeled claim RWE evidence-strategy director would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in biosimilar analytical similarity report, then the action for RWE evidence-strategy director - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Pharmacovigilance finding in biosimilar analytical similarity report that a second reviewer can re-perform - Missing page in biosimilar analytical similarity report after a CMO 483 that maps to the NDA CMC module, if any